Overview
- The Series A totals $47.5 million, led by Samsara Biocapital and Lightstone Ventures with participation from Roivant, YK Bioventures, and Eurofarma Ventures.
- PsiThera, formerly Psivant Therapeutics within Roivant, is now operating independently while retaining Roivant as a backer.
- Eric Shaff, previously CEO of Seres Therapeutics, takes the helm as CEO, with founder Woody Sherman serving as chief innovation officer.
- The QUAISAR computational platform combines quantum chemistry, molecular dynamics, machine learning, and supercomputing to model protein motion and drug behavior.
- Initial programs target the TNF superfamily for oral therapies in immunology, with the company reporting a four‑month hit‑to‑lead advance and planning lead candidate selection next year.